C-NMR Spectra: Bruker DRX-500 Avance instrument using CDCl 3 as applied solvent and TMS as internal standard at 500.1 and 125.7 MHz, respectively.; δ in ppm, J in Hz. Mass spectra were recorded on a Finnigan-MAT-8430EI-MS mass spectrometer; at an ionization potential 70 eV; in m/z (rel. %). Elemental analyses for C, H, and N were performed using a Heraeus CHN-O-Rapid analyzer.
General Procedure

General procedures for the preparation of indolizine derivatives 5 and 11:
A mixture of quinaldine (0.286 g, 2 mmol), pyridine or isoquinoline (4 mmol) and I 2 (0.506 g, 2 mmol) in MeCN (4 mL) was warmed to 60 °C for 2 h. (i-Pr) 2 NEt (0.541 g, 4.2 mmol) and a solution of 1 (2 mmol) in MeCN (1 mL) were then added. The resulting mixture was left at 60 °C overnight. Then, kept in a freezer for 24 h. The precipitate was filtered, 2 separated and recrystallized from n-hexane/AcOEt (1:5) (to give yellow crystals of indolizine
5).
Ethyl 2-(tert-butylamino)-3-(quinolin-2-yl)indolizine-1-carboxylate (5a): , 75.85; H, 6.84; N, 9.83. Found: C, 76.11; H, 6.91; N, 9.90. 5 Formation of isomeric 5f and 5f' in 6:1 ratio: Yellow powder; 141-148 °C; yield: 0.58 g (75%). IR (KBr) (ν max , cm -1 ): 3340, 3112, 3056, 2957, 1700, 1599, 1548, 1487, 1296, 1195 . 
Minor isomer 5f': Ethyl 2-(tert-butylamino)-6-methyl-3-(quinolin-2-yl)indolizine-1-carboxylate (15%)
The NMR data was extracted from the mixture of 5f' and 5f. , 6.84; N, 9.83. Found: C, 76.15; H, 6.79; N, 9.94. 
